Olenox Industries Inc. (OLOX) 股票分析

公司概述

Olenox Industries Inc. operates within the Industrials sector, specifically focusing on the Metal Fabrication industry, where it provides prefabricated modular structures utilizing wood or steel as base materials for both residential and commercial applications across the United States. The company organizes its operations through three distinct segments: Construction, Medical, and Development and Environmental, offering fabricated and finished structural solutions. As of the latest data, Olenox Industries Inc. maintains a market capitalization of $9.90M and employs a workforce of 31 individuals to support its manufacturing and project delivery activities. The company reported an annual revenue of $3.38M over the trailing twelve months, a figure that, when viewed alongside its sub-$10M market cap, indicates a small-cap enterprise with a relatively modest operational footprint and limited revenue generation capacity within the broader industrial landscape.

财务健康

The company reported revenue of $3.38M for the trailing twelve months, yet posted a net income of $-23,143,144, revealing a severe structural deficit where costs significantly exceeded total revenue generation. The EBITDA stood at $-10,233,119, further highlighting the operational challenges the business faces in covering its core operating expenses. Despite the significant accounting losses, the company generated positive free cash flow of $1.46M, which suggests that operational cash generation remains sufficient to cover capital expenditures and debt obligations, providing a degree of financial flexibility often absent in similarly distressed firms. The gross margin is recorded at -63.4%, indicating that the cost of goods sold far exceeds the revenue recognized from sales, while the operating margin of -238.6% and profit margin of 0.0% demonstrate that the company is currently unable to generate profit from its core business activities or bottom-line earnings. In terms of liquidity and leverage, the company holds cash of $3.02M against total debt of $12.19M, resulting in a debt-to-equity ratio of 48.90, which characterizes a highly leveraged balance sheet where liabilities substantially outweigh equity. The current ratio is 0.18, a metric that indicates a critical shortage of liquid assets relative to current liabilities, suggesting potential difficulties in meeting short-term obligations without external financing. Furthermore, the return on equity is -228.4% and the return on assets is -21.8%, metrics that reveal management has been ineffective in generating returns for shareholders or utilizing the asset base to produce profitability during this reporting period.

估值评估

The trailing P/E ratio is listed as N/A due to the absence of positive earnings, and the forward P/E is also N/A, implying that traditional earnings-based valuation models cannot be applied until the company achieves consistent profitability. The price-to-book ratio stands at 0.04, indicating that the market values the company at only a fraction of its book value, which often reflects significant market skepticism regarding the recoverability of its assets or the likelihood of a turnaround. Using alternative valuation metrics, the price-to-sales ratio is 2.93 while the EV/EBITDA is -1.85, suggesting that the market is pricing the stock based on revenue multiple despite negative cash conversion and earnings, a scenario typical for speculative or distressed assets. The stock's price range over the past year has fluctuated between a 52-week low of $0.79 and a 52-week high of $96.00, meaning the current trading price sits at a significant discount relative to the yearly peak but far above the recent trough. The beta value is 2.00, which signifies that the stock's price volatility is twice as high as the broader market, exposing investors to substantially higher risk and potential for sharp price swings during periods of market stress.

Growth & Income

Revenue growth year-over-year is -40.0%, while earnings growth is N/A due to the lack of positive earnings, indicating that the company is contracting significantly in terms of top-line sales rather than expanding. The absence of positive earnings growth means the company cannot be evaluated on the basis of earnings acceleration, and the negative revenue trajectory implies a contraction in demand or a loss of market share within its construction and medical segments. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings are theoretically retained, though the negative earnings make retention irrelevant and suggest capital is being consumed by operational losses rather than reinvested for growth. Overall, the growth and income profile is characterized by substantial revenue contraction, negative profitability, and a complete lack of dividend distribution, presenting a high-risk scenario for investors seeking capital appreciation or income generation from this small-cap industrial entity.